It has been demonstrated that EPA and DHA supplementation may have anti-inflammatory properties in several chronic diseases, namely, diabetes, obesity, and in rheumatoid arthritis, although not with controversy. Systemic lupus erythematosus (SLE) and Antiphospholipid Antibody Syndrome (AAS) are autoimmune diseases characterized by a chronic inflammatory state which is associated with the disease´s clinical symptoms. Thus, we hypothesized that EPA and DHA supplementation may beneficially affect the inflammatory cytokine profile and clinical features of LES and AAS patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Enrollment
22
Subjects will be given 3g/d (1,2g of DHA and 1,8g of EPA) - 5 capsules per day.
Subjects will be given 3g/d of soy oil - 5 capsules per day.
General Hospital - University of Sao Paulo
São Paulo, São Paulo, Brazil
Cytokine profile (serum levels of IL-1B, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-alpha, IFN-y)
Cytokines´ serum levels (pg/ml) will be assessed by Elisa kits.
Time frame: 4 months
Endothelial function
Endothelial function assessed by flow mediated dilatation (FMD).
Time frame: 4 months
Clical features
Disease activity - assessed by SLEDAI score
Time frame: 4 months
Clinical features
Quality of life - assessed by SF-36 questionaire
Time frame: 4 months
Clinical features
Fatigue - assessed by 2 questionaires - Chalders´Fatigue Scale and Fatigue Severity Scale (FSS)
Time frame: 4 months
Clinical features
Body composition - lean (Kg) and fat mass (Kg) assessed by air displacement pletysmography (BOD POD).
Time frame: 4 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.